Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what his planned timeline is for the restoration of a (a) normal and (b) stable supply of Concerta XL; and what contingency measures his Department is putting in place until then.

The Department can confirm that the supply disruptions affecting various strengths of Concerta XL, generic name methylphenidate, tablets have now been fully resolved.

We continue to support the NHS England’s attention deficit hyperactivity disorder (ADHD) taskforce, which brings together expertise from the National Health Service, education, and justice sectors to coordinate a system-wide response to rising demand. In collaboration with NHS England’s national ADHD data improvement plan, we are developing future growth forecasts to support improved demand planning. These forecasts will be shared with industry to help ensure a more responsive and sustainable supply of ADHD medicines.

We continue to work closely with the supplier of Concerta XL tablets to help ensure a stable and increased supply for the United Kingdom’s market. To further strengthen supply chain resilience, we are also engaging with new suppliers to expand the UK supplier base for generic bioequivalents of Concerta XL. This approach will help improve the availability and reduce the risk of future shortages for patients across the UK.

The Department also maintains and regularly updates a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website. This resource supports prescribers and dispensers in making informed decisions with patients. The list is available at the following link:

www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd